This company listing is no longer active
MVRB.F Stock Overview
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Medivir AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.82 |
| 52 Week High | kr0.82 |
| 52 Week Low | kr0.68 |
| Beta | 0.35 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -47.10% |
| 5 Year Change | n/a |
| Change since IPO | -85.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| MVRB.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 2.9% |
| 1Y | n/a | -1.0% | 22.2% |
Return vs Industry: Insufficient data to determine how MVRB.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how MVRB.F performed against the US Market.
Price Volatility
| MVRB.F volatility | |
|---|---|
| MVRB.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MVRB.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MVRB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 9 | Jens Lindberg | www.medivir.com |
Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma.
Medivir AB (publ) Fundamentals Summary
| MVRB.F fundamental statistics | |
|---|---|
| Market cap | US$40.89m |
| Earnings (TTM) | -US$7.26m |
| Revenue (TTM) | US$417.00k |
98.0x
P/S Ratio-5.6x
P/E RatioIs MVRB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MVRB.F income statement (TTM) | |
|---|---|
| Revenue | kr4.31m |
| Cost of Revenue | kr56.38m |
| Gross Profit | -kr52.07m |
| Other Expenses | kr22.90m |
| Earnings | -kr74.96m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 18, 2023
| Earnings per share (EPS) | -1.35 |
| Gross Margin | -1,208.68% |
| Net Profit Margin | -1,740.13% |
| Debt/Equity Ratio | 0% |
How did MVRB.F perform over the long term?
See historical performance and comparison